The concern of generic challenges has long loomed above copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the outlook of similar drug investments. While initial periods saw substantial returns, the patent lapse has created the door for discounted substitutes, likely lowering earnings and creating a significant hazard for shar… Read More